These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 24657936)
41. Anti-inflammatory effects of FTY720 do not prevent neuronal cell loss in a rat model of optic neuritis. Rau CR; Hein K; Sättler MB; Kretzschmar B; Hillgruber C; McRae BL; Diem R; Bähr M Am J Pathol; 2011 Apr; 178(4):1770-81. PubMed ID: 21406175 [TBL] [Abstract][Full Text] [Related]
42. Lung tumor development in the presence of sphingosine 1-phosphate agonist FTY720. Salinas NR; Lopes CT; Palma PV; Oshima CT; Bueno V Pathol Oncol Res; 2009 Dec; 15(4):549-54. PubMed ID: 19214784 [TBL] [Abstract][Full Text] [Related]
43. Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. Oo ML; Thangada S; Wu MT; Liu CH; Macdonald TL; Lynch KR; Lin CY; Hla T J Biol Chem; 2007 Mar; 282(12):9082-9. PubMed ID: 17237497 [TBL] [Abstract][Full Text] [Related]
44. FTY720 induces apoptosis in B16F10-NEX2 murine melanoma cells, limits metastatic development in vivo, and modulates the immune system. Pereira FV; Arruda DC; Figueiredo CR; Massaoka MH; Matsuo AL; Bueno V; Rodrigues EG Clinics (Sao Paulo); 2013 Jul; 68(7):1018-27. PubMed ID: 23917669 [TBL] [Abstract][Full Text] [Related]
45. FTY720 (Fingolimod) attenuates basal and sphingosine-1-phosphate-evoked thyroid cancer cell invasion. Kalhori V; Magnusson M; Asghar MY; Pulli I; Törnquist K Endocr Relat Cancer; 2016 May; 23(5):457-68. PubMed ID: 26935838 [TBL] [Abstract][Full Text] [Related]
46. Recent trials for FTY720 (fingolimod): a new generation of immunomodulators structurally similar to sphingosine. Mansoor M; Melendez AJ Rev Recent Clin Trials; 2008 Jan; 3(1):62-9. PubMed ID: 18474015 [TBL] [Abstract][Full Text] [Related]
47. FTY720 induces apoptosis of chronic myelogenous leukemia cells via dual activation of BIM and BID and overcomes various types of resistance to tyrosine kinase inhibitors. Kiyota M; Kuroda J; Yamamoto-Sugitani M; Shimura Y; Nakayama R; Nagoshi H; Mizutani S; Chinen Y; Sasaki N; Sakamoto N; Kobayashi T; Matsumoto Y; Horiike S; Taniwaki M Apoptosis; 2013 Nov; 18(11):1437-1446. PubMed ID: 23851982 [TBL] [Abstract][Full Text] [Related]
53. Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade. Martin JL; Julovi SM; Lin MZ; de Silva HC; Boyle FM; Baxter RC Breast Cancer Res; 2017 Aug; 19(1):90. PubMed ID: 28778177 [TBL] [Abstract][Full Text] [Related]
54. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system. Brinkmann V Br J Pharmacol; 2009 Nov; 158(5):1173-82. PubMed ID: 19814729 [TBL] [Abstract][Full Text] [Related]
55. Endothelial barrier protection by FTY720 under hyperglycemic condition: involvement of focal adhesion kinase, small GTPases, and adherens junction proteins. Sarai K; Shikata K; Shikata Y; Omori K; Watanabe N; Sasaki M; Nishishita S; Wada J; Goda N; Kataoka N; Makino H Am J Physiol Cell Physiol; 2009 Oct; 297(4):C945-54. PubMed ID: 19657053 [TBL] [Abstract][Full Text] [Related]
56. Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. Saddoughi SA; Gencer S; Peterson YK; Ward KE; Mukhopadhyay A; Oaks J; Bielawski J; Szulc ZM; Thomas RJ; Selvam SP; Senkal CE; Garrett-Mayer E; De Palma RM; Fedarovich D; Liu A; Habib AA; Stahelin RV; Perrotti D; Ogretmen B EMBO Mol Med; 2013 Jan; 5(1):105-21. PubMed ID: 23180565 [TBL] [Abstract][Full Text] [Related]
58. FTY720 attenuates hypoxia-reoxygenation-induced apoptosis in cardiomyocytes. Wang M; Lu L; Liu Y; Gu G; Tao R Exp Mol Pathol; 2014 Oct; 97(2):218-24. PubMed ID: 25034934 [TBL] [Abstract][Full Text] [Related]
59. Synthetic analogs of FTY720 [2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol] differentially regulate pulmonary vascular permeability in vivo and in vitro. Camp SM; Bittman R; Chiang ET; Moreno-Vinasco L; Mirzapoiazova T; Sammani S; Lu X; Sun C; Harbeck M; Roe M; Natarajan V; Garcia JG; Dudek SM J Pharmacol Exp Ther; 2009 Oct; 331(1):54-64. PubMed ID: 19592667 [TBL] [Abstract][Full Text] [Related]
60. [A new therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720)]. Chiba K Nihon Rinsho Meneki Gakkai Kaishi; 2009 Apr; 32(2):92-101. PubMed ID: 19404007 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]